New data shows Eli Lilly's Zepbound outperforms Novo Nordisk's Wegovy in weight loss, with 65% vs 40% of patients achieving ...

Houston-based Empower Pharmacy has repeatedly been admonished by the FDA for failing to follow federal rules that ensure drug ...

Las acciones de las empresas farmacéuticas cayeron en todo el mundo después de que el presidente de EE.UU., Donald Trump, ...

People taking Eli Lilly’s obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk’s Wegovy in ...

Novo Nordisk's competitive position is strengthening, driven by strong sales growth in Wegovy, Ozempic, and rare diseases.